Deep Track Capital’s Pliant Therapeutics PLRX Stock Holding History

Deep Track Capital’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,947,807	Closed	-$4.58M	–	67
2025 Q2	$4.58M	Sell	3,947,807 -1,451,874	-27%	-$2.05M	0.15%	53
2025 Q1	$7.29M	Sell	5,399,681 -572,576	-10%	-$3.48M	0.24%	52
2024 Q4	$78.7M	Hold	5,972,257	–	–	2.93%	10
2024 Q3	$66.9M	Hold	5,972,257	–	–	2.12%	19
2024 Q2	$64.2M	Buy	5,972,257 +222,257	+4%	+$2.87M	1.92%	20
2024 Q1	$85.7M	Hold	5,750,000	–	–	2.45%	19
2023 Q4	$104M	Buy	5,750,000 +250,000	+5%	+$3.8M	3.48%	8
2023 Q3	$95.4M	Buy	5,500,000 +1,450,000	+36%	+$25.1M	3.68%	10
2023 Q2	$73.4M	Buy	4,050,000 +627,943	+18%	+$14.9M	3.4%	12
2023 Q1	$91M	Buy	3,422,057 +1,689,111	+97%	+$48.1M	3.74%	8
2022 Q4	$33.5M	Buy	1,732,946 +333,202	+24%	+$6.97M	1.41%	25
2022 Q3	$29.2M	Buy	+1,399,744	New	+$26.8M	1.34%	27

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Deep Track Capital's PLRX Position: Q3 2025 in Review

Deep Track Capital sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 3,947,807 shares — an estimated $4.58M sold.

Deep Track Capital first reported a position in PLRX in Q3 2022 and held it in 12 quarters. The position peaked at $104M in Q4 2023. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

Deep Track Capital reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
Deep Track Capital sold 3,947,807 Pliant Therapeutics shares in Q3 2025, an estimated $4.58M.
Deep Track Capital first reported a position in Pliant Therapeutics in Q3 2022 and held it in 12 quarters.
Deep Track Capital's Pliant Therapeutics position peaked at $104M in Q4 2023.
99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Deep Track Capital's 13F filing for Q3 2025, filed 14 Nov 2025.